Daniel J. Lippis - Jul 11, 2024 Form 4 Insider Report for Edwards Lifesciences Corp (EW)

Role
CVP, JAPAC
Signature
Linda J. Park, Attorney-in-Fact
Stock symbol
EW
Transactions as of
Jul 11, 2024
Transactions value $
-$24,452
Form type
4
Date filed
7/11/2024, 05:38 PM
Previous filing
Jul 8, 2024
Next filing
Dec 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EW Common Stock Options Exercise $22.6K +500 +2.16% $45.28 23.7K Jul 11, 2024 Direct F1
transaction EW Common Stock Sale -$47.1K -500 -2.11% $94.18 23.2K Jul 11, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EW Employee Stock Option (Right to Acquire) Options Exercise $0 -500 -9.94% $0.00 4.53K Jul 11, 2024 Common Stock 500 $45.28 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2023.

Remarks:

This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.